The global nivolumab injection market is anticipated to grow at a considerable CAGR during the forecast period (2022-2028). Nivolumab injections are the monoclonal antibodies medication used in chemotherapy for the treatment of several diseases, including melanoma, metastatic squamous NSCLC, classical hodgkin lymphoma, and others. The major factor attributing to the growth of the global nivolumab injection market is the rising prevalence of melanoma. According to the American Society of Clinical Oncology (ASCO), around 3.2 million people were diagnosed with melanoma globally in 2020. Around 99,780 adults are estimated to be diagnosed with invasive melanoma in the US alone in 2022. Among these around 57,180 will be men and around 42,600 will be women.
In addition, the rising prevalence of metastatic squamous NSCLC, a type of lung cancer is also boosting the demand for nivolumab injections for its treatment. According to the American Society of Clinical Oncology (ASCO), an estimation of around 2.3 million people were diagnosed with lung cancer across the globe in 2021. Among these, an estimation of around 2,35,760 adults diagnosed with lung cancer is from the US alone. Furthermore, the application of nivolumab injections in the treatment of hodgkin lymphoma is also increasing. According to the American Society of Clinical Oncology (ASCO), around 83,087 people were diagnosed with hodgkin lymphoma across the globe in 2020. It is estimated that around 8540 people will be diagnosed with hodgkin lymphoma in the US alone in 2022.
The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in March 2022, the USFDA approved the use of “Opdivo” along with chemotherapy as a new adjuvant treatment for resectable non-small cell lung cancer in certain adult patients. Opdivo is a 360 mg intravenous nivolumab injection developed by Bristol Mere Squibb (BMS).
(Get 15% Discount on Buying this Report)
Get Sample Copy of Nivolumab Injection Market at: https://orionmarketreports.com/request-sample/?id=104012&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Application
- By Distribution Channel
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape– Bristol Myers Squibb (BMS), AbbVie Inc., China National Pharmaceutical Group Co. Ltd., Ono Pharmaceutical co. Ltd., and Teva Pharmaceuticals Industries Ltd., among others.
A full report Nivolumab Injection Market of is available at: https://orionmarketreports.com/nivolumab-injection-market/104012/
Global Nivolumab Injection Market Report by Segment
By Application
- Melanoma
- Metastatic Squamous NSCLC
- Classical Hodgkin Lymphoma
- Renal Cell Carcinoma
By Distribution Channel
- Hospital Pharmacies
- Retail Drug Stores
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
